3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
2
Gynecologic
2
Genitourinary
2
Conditions
Urinary Bladder Neoplasms
2
Interventions
Magnetic Resonance Spectroscopy
44
Specimen Handling
38
enzalutamide
30
Nivolumab
30
pembrolizumab
28
Docetaxel
23
Gemcitabine
22
apalutamide
20
Prednisone
20
Biopsy
20
Abiraterone Acetate
18
Androgen Antagonists
17
cabozantinib
14
darolutamide
13
abiraterone
13
Radiotherapy
13
Cisplatin
12
enfortumab vedotin
11
Radiation
11
Ipilimumab
11
Pluvicto
10
erdafitinib
9
belzutifan
9
atezolizumab
9
X-Rays
9
Radiosurgery
9
Mitomycin
9
olaparib
8
cabazitaxel
8
Standard of Care
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
tremelimumab
×
Genitourinary
×
30 days
×
Clear all
NCT04960709
2026-06-04
VOLGA
AstraZeneca
Phase 3
Active not recruiting
712 enrolled
NCT03682068
2026-05-28
NILE
AstraZeneca
Phase 3
Active not recruiting
1,246 enrolled